198 related articles for article (PubMed ID: 11697843)
1. Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients.
Quaedvlieg PF; Visser O; Lamers CB; Janssen-Heijen ML; Taal BG
Ann Oncol; 2001 Sep; 12(9):1295-300. PubMed ID: 11697843
[TBL] [Abstract][Full Text] [Related]
2. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
3. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.
Leong WL; Pasieka JL
J Surg Oncol; 2002 Mar; 79(3):180-7. PubMed ID: 11870669
[TBL] [Abstract][Full Text] [Related]
4. [Metastasized carcinoid tumor treated with interferon and octreotide].
Szilvás A; Székely G; Szilvási I; Jakab F
Orv Hetil; 1998 Oct; 139(41):2455-8. PubMed ID: 9805460
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
[TBL] [Abstract][Full Text] [Related]
6. [Management of digestive system carcinoid tumors and carcinoid syndrome].
Mondragón Sánchez RJ; Castillero Pinilla C; Saldívar Moreno C; Oñate Ocaña LF; Ruiz Molina JM; Aiello Crocifoglio V
Rev Gastroenterol Mex; 1998; 63(4):204-10. PubMed ID: 10319670
[TBL] [Abstract][Full Text] [Related]
7. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
[TBL] [Abstract][Full Text] [Related]
8. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
[TBL] [Abstract][Full Text] [Related]
9. Long-standing malignant pancreatic carcinoid treated with octreotide.
Varas-Lorenzo MJ
Rev Esp Enferm Dig; 2010 Nov; 102(11):662-6. PubMed ID: 21142389
[TBL] [Abstract][Full Text] [Related]
10. Metastatic carcinoid tumor: changing patterns of care over two decades.
Townsend A; Price T; Yeend S; Pittman K; Patterson K; Luke C
J Clin Gastroenterol; 2010 Mar; 44(3):195-9. PubMed ID: 19609217
[TBL] [Abstract][Full Text] [Related]
11. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
Imtiaz KE; Monteith P; Khaleeli A
Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099
[TBL] [Abstract][Full Text] [Related]
12. Long-term octreotide treatment of metastatic carcinoid tumor.
Corleto VD; Angeletti S; Schillaci O; Marignani M; Caratozzolo M; Panzuto F; Annibale B; Delle Fave G
Ann Oncol; 2000 Apr; 11(4):491-3. PubMed ID: 10847473
[TBL] [Abstract][Full Text] [Related]
13. [Carcinoid of the appendix. A case report].
Spallitta SI; Termine G; Stella M; Calistro V; Marozzi P
Minerva Chir; 2000; 55(1-2):77-87. PubMed ID: 10832290
[TBL] [Abstract][Full Text] [Related]
14. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
16. Primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease: a case report of a patient on long-term follow-up.
Tohyama T; Matsui K; Kitagawa K
Intern Med; 2005 Sep; 44(9):958-62. PubMed ID: 16258211
[TBL] [Abstract][Full Text] [Related]
17. Octreotide therapy in carcinoid disease.
Bax ND; Woods HF; Batchelor A; Jennings M
Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
[TBL] [Abstract][Full Text] [Related]
18. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
Tomassetti P; Migliori M; Corinaldesi R; Gullo L
Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal carcinoid tumors: diagnosis and treatment.
Stamatakos M; Kontzoglou K; Sargedi C; Tsaknaki S; Iannescu R; Safioleas C; Kaitanidi V; Safioleas M
Chirurgia (Bucur); 2010; 105(6):759-66. PubMed ID: 21351698
[TBL] [Abstract][Full Text] [Related]
20. Use of the somatostatin analogue octreotide acetate in the treatment of encephalopathy associated with carcinoid tumor. Case report.
Siu LL; Chapman W; Moore MJ
Am J Clin Oncol; 1997 Dec; 20(6):558-61. PubMed ID: 9391539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
